Skip to main content

Environmental Exposure

3
Pipeline Programs
3
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
3
[14C]-benzo[a]pyrenePhase 11 trial
[14C]-benzo[a]pyrenePhase 11 trial
[14C]-benzo[a]pyrenePhase 11 trial
Active Trials
NCT03318978Completed8Est. Feb 2024
NCT03631667Completed8Est. Feb 2024
NCT03802721Completed7Est. Feb 2024
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
InterventionN/A2 trials
Active Trials
NCT05258656Recruiting1,800Est. Jun 2028
NCT01244568Completed218Est. Jan 2013
Marker Therapeutics
1 program
Urinary EDC metabolite testingN/A1 trial
Active Trials
NCT06450951Active Not Recruiting600Est. Aug 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Oregon Therapeutics[14C]-benzo[a]pyrene
Oregon Therapeutics[14C]-benzo[a]pyrene
Oregon Therapeutics[14C]-benzo[a]pyrene
Marker TherapeuticsUrinary EDC metabolite testing
Allergy TherapeuticsIntervention
Allergy TherapeuticsIntervention

Clinical Trials (6)

Total enrollment: 2,641 patients across 6 trials

NCT03802721Oregon Therapeutics[14C]-benzo[a]pyrene

Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet

Start: Jan 2019Est. completion: Feb 20247 patients
Phase 1Completed
NCT03631667Oregon Therapeutics[14C]-benzo[a]pyrene

Ultralow Dose PAH Binary Mixture Study

Start: Oct 2018Est. completion: Feb 20248 patients
Phase 1Completed
NCT03318978Oregon Therapeutics[14C]-benzo[a]pyrene

Benzo[a]Pyrene Ultralow Dose-Response Study

Start: Apr 2018Est. completion: Feb 20248 patients
Phase 1Completed
NCT06450951Marker TherapeuticsUrinary EDC metabolite testing

A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals

Start: May 2024Est. completion: Aug 2026600 patients
N/AActive Not Recruiting
NCT05258656Allergy TherapeuticsIntervention

Childhood Activities Nutrition and Development Oversight

Start: Mar 2022Est. completion: Jun 20281,800 patients
N/ARecruiting
NCT01244568Allergy TherapeuticsIntervention

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

Start: Dec 2010Est. completion: Jan 2013218 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,641 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.